Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2020 Earnings Conference Call February 26, 2021 8:30 AM ET Company Participants Tasos Konidaris - Chief Financial Officer Chirag Patel - Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Joe Todisco - Chief Commercial Officers of Generics and Specialty Conference Call Participants David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Elliot Wilbur - Raymond James Greg Gilbert - Truist Securities Balaji Prasad - Barclays Dana Flande ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0546926 (State or other jurisdict ...

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Anastasios Konidaris - EVP & CFO Chirag Patel - Co-Founder, Co-CEO, President & Director Chintu Patel - Co-Founder, Co-CEO & Director Joseph Todisco - EVP & Chief Commercial Officer, Specialty Conference Call Participants Gregory Gilbert - Truist Securities Daniel Busby - RBC Capital Markets Ami Fadia - SVB Leerink David Amsellem - Piper Sandler & Co. Operator Good morning, and welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.01 per share AMRX New York Stock Exchange Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Delaware 32-0546926 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Amneal Pharma ...